Cutaneous Lesions and Clinical Outcomes in Five Cats After Frunevetmab Injections

This case series reports on five cats that experienced cutaneous adverse events following subcutaneous administration of frunevetmab, an anti-nerve growth factor monoclonal antibody used for managing osteoarthritis pain in cats. The cats exhibited moderate to severe pruritus leading to self-inflicted trauma, resulting in lesions such as superficial dermatitis, alopecia, and ulcerations, though no injection site reactions were noted. Symptoms appeared 3-18 days post-injection, with some cats reacting after their first dose and others after subsequent doses. Three cats received additional injections after the initial adverse event, all experiencing similar or more severe reactions. This study is the first to document these specific adverse events and associated histopathological findings with frunevetmab treatment.